

Development and effectiveness of pseudotyped SARS-CoV-2 system

December 6 2021




Fig. 1. Identification of SARS-CoV-2 S protein expression and SARS-CoV-2 pseudotyped virus.(A) Construction and identification of S expressing plasmid. SARS-CoV-2 S protein gene was inserted in the pCDNA3.1 vector. (B) Immunofluorescence assay for S protein expression in pcDNA3.1-SARS-CoV-2 S plasmid. The expression was determined using mouse pAb against SARS-

CoV-2 S protein and convalescent serum samples from COVID-19 patients. (C) Identification of S protein expression in SARS-CoV-2 pseudotyped virus by immunoblot assay. Bands corresponding to SARS-CoV-2 S and HIV-1 p24 proteins were detected at the same sample line in the gel. Credit: Compuscript Ltd

Coronavirus disease 2019 (COVID-19) has become a global pandemic. Currently, SARS-CoV-2 live virus-associated experiments need to be handled in biosafety level 3 (BSL-3) facilities. Previously, researchers had successfully established an HIV-based, pseudotyped virus system for studies on MERS-CoV and Ebola virus. Using the pseudotyped virus system, viral entry associated research, e.g., neutralization assays and in vitro pharmacodynamics, can thus be carried out in the BSL-2 facilities.

In this study, the authors have developed a pseudotyped SARS-CoV-2 system that efficiently operates in a BSL-2 facility. With [transfection](#) of two plasmids into HEK293T cells, the authors developed an HIV-1 core-based pseudotyped virus consisting of SARS-CoV-2 spike protein and found Huh7.5 cell line suitable for analysis of the pseudotyped SARS-CoV-2 system. The authors used the Convalescent serum from 11 COVID-19 patients to compare the results of SARS-CoV-2 live-virus microneutralization and the pseudotyped SARS-CoV-2 system and notice a significant correlation between the results obtained by the two methods.

The pseudotyped SARS-CoV-2 system, developed in this study, seems highly reliable for conducting the SARS-CoV-2 viral entry associated research in a BSL-2 facility. The system is suitable for high-throughput analysis and R&D of vaccines and drugs.

More information: Ren Yang et al, Development and effectiveness of

pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro, *Biosafety and Health* (2020).
[DOI: 10.1016/j.bsheal.2020.08.004](https://doi.org/10.1016/j.bsheal.2020.08.004)

Provided by Compuscript Ltd

Citation: Development and effectiveness of pseudotyped SARS-CoV-2 system (2021, December 6) retrieved 9 May 2024 from
<https://medicalxpress.com/news/2021-12-effectiveness-pseudotyped-sars-cov-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.